ClinicalTrials.Veeva

Menu
T

Treasure Valley Medical Research | Boise, ID

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
CDX-0159
Dupilumab
Remibrutinib
Rocatinlimab
Lebrikizumab
LOU064
UPB-101
Verekitug
Vonoprazan

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

32 of 46 total trials

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

The purpose of this trial is:1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to \< 18 year...

Enrolling
Chronic Spontaneous Urticaria
Drug: placebo
Drug: LOU064 (blinded)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in...

Active, not recruiting
Chronic Spontaneous Urticaria
Biological: barzolvolimab
Drug: Matching Placebo

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Enrolling
Asthma
Drug: Placebo
Drug: Rocatinlimab
Status recently updated

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urtic...

Not yet enrolling
Enrolling
Chronic Spontaneous Urticaria
Biological: Matching placebo
Biological: barzolvolimab

This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed...

Enrolling
Eosinophilic Oesophagitis
Drug: Placebo
Drug: Dupilumab

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.

Enrolling
Prurigo Nodularis
Other: Matching Placebo
Biological: barzolvolimab

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in...

Active, not recruiting
Chronic Inducible Urticaria
Drug: Matching Placebo
Biological: barzolvolimab

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adult Eosinophilic Esophagitis patients.

Enrolling
Eosinophilic Esophagitis
Biological: barzolvolimab
Drug: Matching Placebo

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal pol...

Enrolling
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Drug: Standard therapy for INCS
Drug: LY3650150

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...

Enrolling
Atopic Dermatitis
Eczema
Drug: Placebo
Drug: Lebrikizumab
Locations recently updated

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib Dose B
Drug: Upadacitinib Dose A
Locations recently updated

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling
Hidradenitis Suppurativa
Drug: Upadacitinib
Drug: Placebo
Locations recently updated

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with mode...

Enrolling
Atopic Dermatitis
Eczema
Drug: Lebrikizumab
Drug: Placebo

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab
Locations recently updated

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subje...

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension...

Enrolling
Chronic Inducible Urticaria
Drug: Remibrutinib
Other: Placebo

Trial sponsors

AbbVie logo
Celldex Therapeutics logo
Novartis logo
Amgen logo
Lilly logo
E
Pfizer logo
Phathom Pharmaceuticals logo
Regeneron Pharmaceuticals logo
Sanofi logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems